In this retrospective cohort study, researchers aimed to quantify excess all-cause mortality among 5-year survivors of ...
Welltica+ on MSN
Surviving Hodgkin lymphoma may leave you at double the long-term mortality risk, even years later
New MD Anderson research finds five-year survivors still die at roughly twice the expected rate.
Hodgkin lymphoma survivors had nearly twice the mortality of the general United States population, with excess deaths across ...
Long term trends in Hodgkin's lymphoma incidence in the United States and Puerto Rico, 1999 to 2022.
Lymphoma epidemiology in Syria: A 2024 analysis from the nation's primary oncology referral center. Novel triplet combination of orelabrutinib, lenalidomide, and rituximab as frontline therapy for ...
Patients with early-stage Hodgkin lymphoma had impressive response rates when treated with a novel combination of therapies—brentuximab vedotin and nivolumab combined with chemotherapy drugs ...
In a phase 2 single-arm trial, an 8-week dose-dense modified Stanford V chemotherapy regimen allowed most evaluable pediatric patients with low-risk Hodgkin lymphoma to avoid radiation therapy. Among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results